| Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases (NCT00623766) | Bristol-Myers Squibb | 2008-07-01 |
| Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors (NCT00722228) | Hadassah Medical Organization | 2008-07-01 |
| Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies (NCT00710515) | AstraZeneca | 2008-07-01 |
| Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma (NCT00613509) | Sanofi Pasteur, a Sanofi Company | 2008-06-01 |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors (NCT00625456) | Jennerex Biotherapeutics | 2008-06-01 |
| A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma (NCT00746746) | Ochsner Health System | 2008-06-01 |
| Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma (NCT00701987) | Advanced Life Sciences, Inc. | 2008-06-01 |
| Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients (NCT00706992) | National Cancer Institute (NCI) | 2008-06-01 |
| Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma (NCT00716495) | AGIRx Ltd. | 2008-06-01 |
| Melanoma Molecular Profiling Analysis (NCT00889980) | University of Pittsburgh | 2008-05-01 |
| Safety Study of Modified Vaccinia Virus to Cancer (NCT00574977) | David Bartlett | 2008-05-01 |
| The Impact of Total Body Skin Examination on Skin Cancer Detection (NCT00765193) | Medical University of Graz | 2008-05-01 |
| Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma (NCT00671554) | Prisma Health-Upstate | 2008-04-01 |
| Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma (NCT00671918) | Navidea Biopharmaceuticals | 2008-04-01 |
| NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma (NCT00667082) | Celgene | 2008-03-01 |
| Pilot Study of Infrared Imaging of Cutaneous Melanoma (NCT00937690) | University of Virginia | 2008-03-01 |
| Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04) (NCT00636558) | Viralytics | 2008-02-29 |
| Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors (NCT00610389) | Clinica Universidad de Navarra, Universidad de Navarra | 2008-02-01 |
| Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma (NCT00623402) | University Hospital Schleswig-Holstein | 2008-01-01 |
| Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma (NCT00590824) | University of Wisconsin, Madison | 2007-12-17 |
| A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) (NCT00600496) | AstraZeneca | 2007-12-14 |
| Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma (NCT00597272) | Memorial Sloan Kettering Cancer Center | 2007-12-01 |
| A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma (NCT00585000) | AstraZeneca | 2007-12-01 |
| Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma (NCT00521053) | Provectus Pharmaceuticals | 2007-09-01 |
| Can We Miss Pigmented Lesions in Psoriasis Patients? (NCT01053819) | University of Alabama at Birmingham | 2007-09-01 |
| Characterization of the Melanoma-Specific Immune Response (NCT00368615) | University of California, Davis | 2007-08-01 |
| Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma (NCT00522834) | Synta Pharmaceuticals Corp. | 2007-08-01 |
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma (NCT00924001) | National Cancer Institute (NCI) | 2007-08-01 |
| Trial of Dacarbazine With or Without Genasense in Advanced Melanoma (NCT00518895) | Genta Incorporated | 2007-07-01 |
| High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes (NCT00463892) | Redwood Regional Medical Group | 2007-06-01 |
| Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma (NCT00513604) | National Cancer Institute (NCI) | 2007-06-01 |
| Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes (NCT00509496) | National Cancer Institute (NCI) | 2007-06-01 |
| Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma (NCT00598507) | H. Lee Moffitt Cancer Center and Research Institute | 2007-05-01 |
| A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen (NCT00623831) | Ludwig Institute for Cancer Research | 2007-05-01 |
| Vaccination Plus Ontak in Patients With Metastatic Melanoma (NCT00515528) | University of Chicago | 2007-04-23 |
| A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. (NCT00378482) | AstraZeneca | 2007-03-05 |
| Biochemotherapy With Temozolomide for Metastatic Melanoma (NCT00505635) | M.D. Anderson Cancer Center | 2007-03-01 |
| Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma (NCT00673361) | Duke University | 2007-03-01 |
| Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells (NCT00482105) | University of California, Davis | 2007-03-01 |
| High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) (NCT00457418) | Merck Sharp & Dohme LLC | 2007-02-20 |
| Study of XL281 in Adults With Solid Tumors (NCT00451880) | Exelixis | 2007-02-01 |
| A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma (NCT00434252) | Genentech, Inc. | 2007-02-01 |
| A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma (NCT00429312) | Jennerex Biotherapeutics | 2007-02-01 |
| Evaluation of Pigmented Skin Lesions With MelaFind(R) System (NCT00434057) | MELA Sciences, Inc. | 2007-01-01 |
| PTK/ZK in Disseminated Malignant Melanoma (NCT00615160) | Michael Weichenthal | 2006-12-01 |
| Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer (NCT00405405) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2006-12-01 |
| Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma (NCT00418496) | Ohio State University Comprehensive Cancer Center | 2006-11-08 |
| Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma (NCT00610857) | Ahmad Tarhini | 2006-11-01 |
| Abraxane and Temodar Plus Genasense in Advanced Melanoma (NCT00409383) | Genta Incorporated | 2006-11-01 |
| Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo (NCT00574392) | Memorial Sloan Kettering Cancer Center | 2006-11-01 |
| Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting (NCT00412425) | M.D. Anderson Cancer Center | 2006-11-01 |
| Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns (NCT00518050) | Memorial Sloan Kettering Cancer Center | 2006-10-01 |
| Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease (NCT00897312) | Vanderbilt-Ingram Cancer Center | 2006-10-01 |
| Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma (NCT00383851) | Attenuon | 2006-09-01 |
| A Phase I/II Study of Sunitinib and Dacarbazine (NCT00496223) | H. Lee Moffitt Cancer Center and Research Institute | 2006-09-01 |
| Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma (NCT00356460) | Genzyme, a Sanofi Company | 2006-09-01 |
| Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides (NCT00365937) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2006-08-01 |
| Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients (NCT00525031) | M.D. Anderson Cancer Center | 2006-08-01 |
| Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma (NCT00324155) | Bristol-Myers Squibb | 2006-08-01 |
| 131-I-TM-601 Study in Adults With Solid Tumors (NCT00379132) | TransMolecular | 2006-08-01 |
| Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma (NCT01944709) | Prof. Dr. Silke Gillessen | 2006-08-01 |
| Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response (NCT00680589) | Memorial Sloan Kettering Cancer Center | 2006-07-01 |
| Randomised Study to Compare the Efficacy of AZD6244 vs TMZ (NCT00338130) | AstraZeneca | 2006-07-01 |
| A Study to Assess APO866 for the Treatment of Advanced Melanoma (NCT00432107) | Valerio Therapeutics | 2006-07-01 |
| Sample Collection From Melanoma Patients (NCT00507325) | M.D. Anderson Cancer Center | 2006-06-13 |
| Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody (NCT00431275) | AstraZeneca | 2006-06-01 |
| A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies (NCT00162123) | Bristol-Myers Squibb | 2006-05-01 |
| Prospective Measurement of Post-Treatment Lymphedema (NCT00495950) | M.D. Anderson Cancer Center | 2006-05-01 |
| Safety of TKI258 in Advanced/Metastatic Melanoma Subjects (NCT00303251) | Novartis Pharmaceuticals | 2006-04-01 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (NCT01851408) | National Cancer Institute (NCI) | 2006-04-01 |
| A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma (NCT00289627) | Bristol-Myers Squibb | 2006-04-01 |
| Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600) (NCT00723710) | Merck Sharp & Dohme LLC | 2006-04-01 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (NCT00349206) | National Cancer Institute (NCI) | 2006-04-01 |
| Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma (NCT00289640) | Bristol-Myers Squibb | 2006-04-01 |
| CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy (NCT00257205) | AstraZeneca | 2006-03-01 |
| Confocal Reflectance Microscopy of Shave-Biopsy Sites on Skin in Vivo. (NCT00601185) | Memorial Sloan Kettering Cancer Center | 2006-02-14 |
| Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients (NCT00527657) | M.D. Anderson Cancer Center | 2006-02-09 |
| Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma (NCT00338377) | M.D. Anderson Cancer Center | 2006-02-01 |
| An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 (NCT00818480) | Astellas Pharma Inc | 2006-02-01 |
| Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma (NCT01462773) | Ohio State University Comprehensive Cancer Center | 2006-01-01 |
| A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma (NCT00289016) | BioVex Limited | 2005-12-01 |
| Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node) (NCT02434107) | University Hospital Tuebingen | 2005-12-01 |
| Imatinib in Adult Patients With Metastatic Ocular Melanoma (NCT00421317) | Centre Oscar Lambret | 2005-12-01 |
| A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma (NCT00281541) | Astellas Pharma Inc | 2005-11-01 |
| Melanoma Vaccine With Peptides and Leuprolide (NCT00254397) | M.D. Anderson Cancer Center | 2005-11-01 |
| FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma (NCT00104884) | ECOG-ACRIN Cancer Research Group | 2005-10-04 |
| A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma (NCT00272415) | Genentech, Inc. | 2005-10-01 |
| Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC) (NCT01009177) | Actelion | 2005-09-30 |
| Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma (NCT00707161) | University of Utah | 2005-09-01 |
| Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma (NCT00199901) | Ludwig Institute for Cancer Research | 2005-09-01 |
| Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma (NCT00412581) | M.D. Anderson Cancer Center | 2005-09-01 |
| Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection (NCT00588341) | Memorial Sloan Kettering Cancer Center | 2005-09-01 |
| Intralesional PV-10 Chemoablation of Metastatic Melanoma (NCT00219843) | Provectus Pharmaceuticals | 2005-08-01 |
| Tailored Intervention for Melanoma Patient's Families (NCT00816374) | Fox Chase Cancer Center | 2005-08-01 |
| Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine (NCT00124124) | Dr. Nina Bhardwaj | 2005-07-01 |
| Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma (NCT00257465) | AVAX Technologies | 2005-06-01 |
| 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology (NCT00207298) | British Columbia Cancer Agency | 2005-06-01 |
| Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma (NCT00130442) | Cellxpert Biotechnology Corp. | 2005-06-01 |
| Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma (NCT00200577) | Nantes University Hospital | 2005-05-01 |
| A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma (NCT00246012) | Centocor, Inc. | 2005-05-01 |